Twist Bioscience CorpNASDAQ:TWST
- LAST PRICE53.9000
- TODAY'S CHANGE (%)0.3400 (0.6348%)
- Bid / Lots51.6400/ 2
- Ask / Lots54.8000/ 1
- Open / Previous Close53.6100 / 53.5600
- Day Range
- 52 Week Range
- Volume811,154
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TWST |
|---|---|---|
| 02:26 ET | 2791 | 52.95 |
| 02:27 ET | 2305 | 53.03 |
| 02:29 ET | 3369 | 52.96 |
| 02:31 ET | 9136 | 53.005 |
| 02:33 ET | 1532 | 52.99 |
| 02:36 ET | 700 | 53.01 |
| 02:38 ET | 2277 | 53.02 |
| 02:40 ET | 1550 | 52.96 |
| 02:42 ET | 1170 | 52.895 |
| 02:44 ET | 1742 | 52.86 |
| 02:45 ET | 1625 | 52.88 |
| 02:47 ET | 2032 | 52.87 |
| 02:49 ET | 2152 | 53.02 |
| 02:51 ET | 1772 | 53.35 |
| 02:54 ET | 700 | 53.21 |
| 02:56 ET | 100 | 53.22 |
| 02:58 ET | 1000 | 53.2 |
| 03:00 ET | 100 | 53.21 |
| 03:02 ET | 2172 | 53.43 |
| 03:05 ET | 2513 | 53.42 |
| 03:07 ET | 800 | 53.34 |
| 03:09 ET | 12437 | 53.45 |
| 03:12 ET | 4947 | 53.35 |
| 03:14 ET | 2500 | 53.555 |
| 03:16 ET | 500 | 53.69 |
| 03:18 ET | 800 | 53.77 |
| 03:20 ET | 3103 | 53.95 |
| 03:21 ET | 900 | 53.95 |
| 03:23 ET | 2261 | 54.015 |
| 03:25 ET | 1200 | 53.865 |
| 03:27 ET | 200 | 53.8 |
| 03:30 ET | 1206 | 53.705 |
| 03:32 ET | 2008 | 53.86 |
| 03:34 ET | 2947 | 53.95 |
| 03:36 ET | 2881 | 53.665 |
| 03:38 ET | 1789 | 53.71 |
| 03:39 ET | 900 | 53.605 |
| 03:41 ET | 4553 | 53.66 |
| 03:43 ET | 2102 | 53.68 |
| 03:45 ET | 2509 | 53.46 |
| 03:48 ET | 2891 | 53.52 |
| 03:50 ET | 2826 | 53.535 |
| 03:52 ET | 4017 | 53.75 |
| 03:54 ET | 9008 | 53.82 |
| 03:56 ET | 12930 | 53.87 |
| 03:57 ET | 20578 | 53.765 |
| 03:59 ET | 41102 | 53.9 |
Jul 18, 2024
Twist Bioscience Announces Clinical Progression of Pure Biologics' Antibody Candidate Discovered Using Twist's Antibody Libraries, from 8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
8:00AM ET on Thursday Jul 18, 2024 by Dow Jones
Jul 11, 2024
Press Release: Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024, from 8:04AM ET on Thursday Jul 11, 2024 by Dow Jones
8:04AM ET on Thursday Jul 11, 2024 by Dow JonesTwist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024, from 8:00AM ET on Thursday Jul 11, 2024 by Dow Jones
8:00AM ET on Thursday Jul 11, 2024 by Dow Jones
Jul 10, 2024
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies, from 8:00AM ET on Wednesday Jul 10, 2024 by Dow Jones
8:00AM ET on Wednesday Jul 10, 2024 by Dow Jones
Jul 9, 2024
DJ Twist Bioscience Is Maintained at Buy by Goldman Sachs, from 10:56AM ET on Tuesday Jul 09, 2024 by Dow Jones
10:56AM ET on Tuesday Jul 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Twist Bioscience Corp | 3.3B | -16.1x | --- |
TG Therapeutics Inc | 3.4B | 95.2x | --- |
Arrowhead Pharmaceuticals Inc | 3.5B | -6.7x | --- |
ADMA Biologics Inc | 3.1B | -654.9x | --- |
MorphoSys AG | 2.8B | -5.4x | --- |
Denali Therapeutics Inc | 3.3B | -22.2x | --- |
Company Information
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
Contact Information
- Headquarters
- 681 Gateway Blvd.SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 408-410-0105
- Fax
- 302-531-3150
Executives
- Chairman of the Board, Chief Executive Officer
- Emily Leproust
- President, Chief Operating Officer
- Patrick Finn
- Chief Financial Officer
- Adam Laponis
- Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer
- Dennis Cho
- Senior Vice President - Advanced Development, General Manager of Data Storage and Director
- William Banyai
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
|---|---|
Revenue (TTM) | $277.5M |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-3.35 |
Book Value | $10.83 |
P/E Ratio | -16.1x |
Price/Sales (TTM) | 11.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -74.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
